Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Palatin Technologies's Enterprise Value is $9.54 Mil.
Palatin Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.24 Mil. Therefore, Palatin Technologies's EV-to-EBIT ratio for today is -1.53.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Palatin Technologies's Enterprise Value is $9.54 Mil.
Palatin Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.14 Mil. Therefore, Palatin Technologies's EV-to-EBITDA ratio for today is -1.55.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Palatin Technologies (LTS:0KF3) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Palatin Technologies's current Enterprise Value is $9.54 Mil.
Palatin Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.24 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Palatin Technologies's current Enterprise Value is $9.54 Mil.
Palatin Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.14 Mil.
Palatin Technologies's current Enterprise Value is $9.54 Mil.
Palatin Technologies's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.88 Mil.
Palatin Technologies's current Enterprise Value is $9.54 Mil.
Palatin Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.93 Mil.
Palatin Technologies's current Enterprise Value is $9.54 Mil.
Palatin Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Palatin Technologies Enterprise Value Related Terms
Palatin Technologies Enterprise Value Historical Data
* Premium members only.
The historical data trend for Palatin Technologies's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0KF3 vs BIVI, NCEL, KTTA: Enterprise Value Comparison
For the Biotechnology subindustry, Palatin Technologies's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Palatin Technologies Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Palatin Technologies's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Palatin Technologies's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Palatin Technologies's Enterprise Value for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Palatin Technologies (LTS:0KF3) has a Enterprise Value of $9.54 Mil as of Sep. 22, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Palatin Technologies and its competitors.
Is Palatin Technologies' Enterprise Value too high?
Palatin Technologies' current Enterprise Value is $9.54 Mil. Overall, Palatin Technologies has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Palatin Technologies' Enterprise Value compare to BIVI and NCEL?
Palatin Technologies' Enterprise Value of $9.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Palatin Technologies and its competitors. Palatin Technologies's current Enterprise Value is $9.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palatin Technologies stock overvalued right now?
Based on GuruFocus' analysis, Palatin Technologies (LTS:0KF3) is currently considered Possible Value Trap. The stock's GF Value™ is $51.03, compared to a current price of $11.14 — trading 78.2% below its estimated fair value. The current Enterprise Value is $9.54 Mil. Palatin Technologies' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Palatin Technologies (LTS:0KF3), the current Enterprise Value is $9.54 Mil as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Palatin Technologies (LTS:0KF3) Overvalued in 2026?
Based on GuruFocus' analysis, Palatin Technologies stock appears to be undervalued.
The current stock price of $11.14 is trading 78.2% below its estimated GF Value™ of $51.03.
GuruFocus considers Palatin Technologies to be Possible Value Trap.
Key valuation signals for LTS:0KF3:
Enterprise Value: $9.54 Mil
GF Value™: $51.03 vs. price of $11.14 (78.2% below fair value)
No single metric tells the full story. See the LTS:0KF3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Palatin Technologies Inc. is a biopharmaceutical company that develops receptor-specific peptide therapeutics based on molecules that modulate the melanocortin receptor system. Its pipeline targets diseases with unmet medical needs, with programs focused on melanocortin-1 receptor (MC1R) agonists for inflammatory and dermatologic conditions and melanocortin-4 receptor (MC4R) agonists for metabolic and other indications. The company's most commercially advanced product is bremelanotide, an MC4R agonist marketed as Vyleesi for hypoactive sexual desire disorder in premenopausal women, which was approved by the FDA in 2019 and is licensed to a commercial partner in the United States. Palatin operates in a single business segment, life sciences, and generates revenue primarily through licensing fees, milestone payments, royalties, and collaboration agreements rather than direct product sales. The company is headquartered in Cranbury, New Jersey, and its activities are concentrated in the United States.
45GF Score
Get the complete analysis for LTS:0KF3
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KF3 has been successfully added to your 
